Feedback from a published article by Frans J Cronje et al. in ACTA Scientific Neurology (ISSN: 2582-1121) Volume 7, Issue 7, July 2024

This case study explores the effects of the KB220, a nutraceutical Neuroadaptagen SYNAP, on a 26-year-old male with multiple neuropsychiatric diagnoses including ADHD, PTSD, and sensory integration disorder. Post-administration EEG analysis revealed significant changes: a 23.5% reduction in Delta activity, and increases in Theta (10.5%), Alpha (25%), and Beta (11%), suggesting enhanced cognitive function and dopamine homeostasis. These findings demonstrate SYNAP’s potential for improving cognitive performance in people with similar dopamine disfunction disorders.

Read the full article: https://actascientific.com/ASNE/pdf/ASNE-07-0756.pdf